Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dystrophin messenger ribonucleic acid
- Development stage
- Preclinical
- Lead developer
- Factor Bioscience
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Gene Therapies
- Administration
- Intravenous, Intramuscular, Intranasal, Intramyocardial, Oral, Intrathecal
01
Overview
Dystrophin messenger ribonucleic acid (mRNA) is a preclinical therapeutic candidate being developed by Factor Biosciences Therapeutics for the treatment of Duchenne Muscular Dystrophy (DMD). This program utilizes mRNA-mediated in vivo gene editing to target and potentially correct mutations in the dystrophin gene, or to facilitate the expression of a functional dystrophin protein. By leveraging Factor's proprietary mRNA and nucleic-acid delivery technologies, the therapy aims to restore dystrophin levels in muscle tissues, addressing the underlying cause of muscle degeneration. The asset is currently in the preclinical stage of development as part of Factor's internal pipeline.
- Other names
- dystrophin mRNA
02
Targets
DMD (Dystrophin)
Beyond the preview
Go deeper on dystrophin messenger ribonucleic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dystrophin messenger ribonucleic acid.